PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fluocortolone Pivalate→

Fluocortolone Pivalate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
29205-06-9
Molecular formula
C27H37FO5
Molecular weight
460.6 g/mol
Drug class
Topical glucocorticoid corticosteroid
Mechanism of action
Fluocortolone is a glucocorticoid that activates intracellular glucocorticoid receptors and suppresses inflammatory mediator production and immune-cell activity in skin, reducing inflammation, erythema and pruritus. The pivalate ester influences the topical formulation and skin delivery.
Indications / reported uses
  • Topical treatment of inflammatory and pruritic dermatoses responsive to corticosteroids, including selected eczema and dermatitis presentations, according to the specific product authorisation.

Sources: https://www.medsafe.govt.nz/profs/class/Agendas/agen26-Fluocortolone-report.pdf · https://meshb.nlm.nih.gov/record/ui?ui=D005448

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fluocortolone Pivalate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluocortolone Pivalate Permitted Daily Exposure (PDE) report (the Fluocortolone Pivalate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluocortolone Pivalate Occupational Exposure Limit (OEL) report (the Fluocortolone Pivalate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.